Login / Signup

Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients.

Sofia FloudaEvgenia EmmanouilidouAnastasios KaramanakosDimitra KoumakiDimitrios Katsifis-NezisArgyro RepaGeorge K BertsiasDimitrios BoumpasAntonis Fanouriakis
Published in: Lupus (2024)
Anifrolumab is highly effective in various skin manifestations of SLE, even after prior failure to multiple treatments.
Keyphrases
  • systemic lupus erythematosus
  • end stage renal disease
  • disease activity
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • wound healing
  • patient reported outcomes